On setting expectations for a SARS-CoV-2 Vaccine

I have been fascinated with infectious diseases for 36 years and pandemics specifically since my introductory Pathobiology course at University. I recall interviewing my paternal grandmother and other friends her age that lived through the 1918 pandemic and outbreaks in the Belgian Congo.

Fast forward 20 years and today, as predicted nearly to the year by my pathobiology instructors, we are in the throes of another pandemic. Dr. David H Canaday, MD and Dr. Stefan Gravenstein, MD, MPH have written about the international collaborations to develop a vaccine for SARS-CoV-2. The full text article can be accessed here.

AUTHORS
: David H Canaday, MD, Stefan Gravenstein, MD, MPH

David H. Canaday, MD
Division of Infectious Diseases
Case Western Reserve University Division of Infectious Diseases
Geriatric Research, Education and Clinical Center (GRECC)
Cleveland Veterans Administration Medical Center Cleveland, OH, U.S.A.

Stefan Gravenstein, MD, MPH
Alpert Medical School and School of Public Health,
Brown University
Providence Veteran Administration Medical Center Providence, RI, U.S.A.

ABSTRACT: The global coronavirus pandemic is unlike any other since 1918. A century of dramatic medical advances has produced a public expectation that the medical field will rapidly provide solutions to restore normalcy. In under 6 months, since SARS-CoV-2 was identified, the massive international effort to develop a SARS-CoV-2 vaccine has generated more than 140 vaccines in different stages of development with 9 already recruiting into clinical trials posted on clinicaltrials.gov. The long-term strategy to handle COVID-19 will almost certainly rely on vaccines. But, what type of protection can we realistically expect to achieve from vaccines and when?

Published by Oxford University Press for the Infectious Diseases Society of America 2020. This work is written by (a) US Government employee(s) and is in the public domain in the US.

This work is written by (a) US Government employee(s) and is in the public domain in the US.

DOI: Clinical Infectious Diseases, ciaa726, 
https://doi.org/10.1093/cid/ciaa726

PUBLISHED:

04 June 2020

SARS COV2 Vaccine.jpg